| 主权项 |
1. A method for predicting prognosis of a cancer patient, or for identifying a cancer patient in need of adjuvant therapy, or for monitoring the progression of a tumor in a patient, comprising:
obtaining a tissue sample from the patient; and measuring the levels of two or more biomarkers in the sample or determining the nucleotide or amino acid sequence of one or more biomarkers in the sample, wherein the biomarkers are selected from the group consisting of FSCN1, KIF2C, DEPDC1, ACP5, ANLN, ASF1B, BRRN1, BUB1, CDC2, CENPM, ELTD1, EXT1, HCAP-G, HMGB1, HMGB2, HOXA1, HSF1, ITGB3BP, KIF20A, KNTC2, MCM7, MTHFD2, NASP, PLVAP, PTP4A3, RNF2, SPAG5, TGM2, UBE2C, UCHL5, VSIG4, HNRPR, CDC20, PRIM2A, HRSP12, ENY2, TMEM141, RECQL, STK3, MX2, CDCA1, CEP68, SPBC25, CDC25C, GRID1, PRIM1, DUT, RRAD, BIRC5, and PGEA1, wherein the measured levels, or a mutation in the determined sequence as compared to a reference sequence, is indicative of the prognosis of the cancer patient, or indicates that the patient is in need of adjuvant therapy, or is indicative of the progression of the tumor in the patient. |
